Cancer statistics, 2017. CA Cancer J Clin, 2017. ,
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII), American Journal of Cancer Research. e-Century Publishing Corporation, vol.5, issue.9, pp.2892-911, 2015. ,
Targeted therapy in non-small-cell lung cancer--is it becoming a reality?, Nat Rev Clin Oncol, vol.7, issue.7, pp.401-415, 2010. ,
,
, Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer, Frontiers in Medicine. Frontiers Media S.A, vol.4, p.4, 2017.
Cancer immunotherapy: the beginning of the end of cancer, BMC Med. London: BioMed Central, vol.14, p.73, 2016. ,
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer, Nat Rev Clin Oncol, vol.11, issue.1, pp.24-37, 2014. ,
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat Rev Cancer, vol.16, issue.5, pp.275-87, 2016. ,
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells, Int Immunol, vol.21, 2009. ,
Biomarqueurs prédictifs de l'efficacité des inhibiteurs de checkpoint immunitaire dans le traitement des cancers, Immunothérapie et cancer, vol.5239, issue.1, p.1 ,
,
, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, 2015.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, vol.389, pp.255-65, 2017. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-50, 2016. ,
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, vol.375, 2016. ,
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology, vol.17, pp.1497-508, 2016. ,
Biomarkers in Early-Stage Non-Small Cell Lung Cancer: Current Concepts and Future Directions, J Thorac Oncol, vol.9, issue.11, pp.1609-1626, 2014. ,
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch, vol.468, pp.511-536, 2016. ,
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project, J Thorac Oncol, vol.12, issue.2, pp.208-230, 2017. ,
, , p.24
Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer, JAMA Oncol ,
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? Expert Review of Molecular Diagnostics ,
, , vol.17, pp.1097-108, 2017.
A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study, Clin Lung Cancer, vol.17, 2016. ,
Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer, N Engl J Med, vol.373, 2015. ,
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis, Critical Reviews in Oncology/Hematology, vol.101, pp.75-85, 2016. ,
First EQA Results for PD-L1, pp.1-15, 2017. ,
Atlas of PD-L1 immunohistochemistry testing in lung cancer ,
, , 2017.
,
, Immunohistochimie PD-1/PD-L1 en oncologie thoracique : où en sommesnous ?, Immunothérapie et cancer, vol.5239, issue.1, p.1
04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC, Journal of Thoracic Oncology, vol.12, issue.1, 2017. ,
Tests immunohistochimiques PD-L1 dans les cancers du poumon non à petites cellules : recommandations par le groupe PATTERN de pathologistes thoraciques, Immunothérapie et cancer, vol.38, issue.2, pp.110-135, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01927078
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer, Annals of Oncology, vol.29, issue.4, pp.953-961, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01926681
Antibodies to the cytoplasmic domain of PD-L1 most clearly delineate cell membranes in immunohistochemical staining, Cancer Immunology Research, vol.3, issue.12, pp.1308-1323, 2015. ,
Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma, Applied Immunohistochemistry & Molecular Morphology, vol.26, issue.2, p.83, 2018. ,
Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach, Clinical Lung Cancer, vol.18, issue.2, pp.220-228, 2017. ,
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms, vol.12, p.183023, 2017. ,
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, N Engl J Med. Massachusetts Medical Society, vol.372, issue.21, pp.2018-2046, 2015. ,
Expression de la protéine PD-L1 par immunohistochimie dans le cancer du poumon non à petites cellules, pp.1-53, 2017. ,
Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary 26 ,
, Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores, The American Journal of Surgical Pathology
, Biomarqueurs des immunothérapies anti-PD-1/PD-L1: facteurs cliniques, histologiques et immunohistochimiques associés au statut PD-L1, pp.1-75, 2016.
Quantitative assessment of the heterogeneity of PD-L1 expression in nonsmall-cell lung cancer, JAMA Oncol, vol.1, 2016. ,
Programmed death ligand-1 expression in non-small cell lung cancer, Lab Invest. United States & Canadian Academy of Pathology, vol.94, issue.1, pp.107-123, 2013. ,
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of Oncology, vol.27, issue.1, pp.147-53, 2015. ,
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non Small-Cell Lung Cancer, Clinical Lung Cancer, vol.16, issue.5, pp.385-90, 2015. ,
Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer, Histopathology, vol.72, issue.3, pp.449-59, 2018. ,
Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples, Clinical Lung Cancer, vol.18, issue.6, p.682, 2017. ,
DOI : 10.1016/j.cllc.2017.04.014
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas, Mod Pathol. United States & Canadian Academy of Pathology, vol.29, issue.10, pp.1165-72, 2016. ,
DOI : 10.1038/modpathol.2016.117
URL : https://www.nature.com/articles/modpathol2016117.pdf
A Quantitative Comparison of Antibodies to PD-L1, JAMA Oncol, 2016. ,
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer, Journal of Thoracic Oncology, vol.13, issue.3, pp.367-76, 2018. ,
DOI : 10.1016/j.jtho.2017.11.112
URL : http://www.jto.org/article/S155608641733054X/pdf
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and testvalidation metrics, Diagnostic Pathology, vol.13, issue.1, p.12, 2018. ,
DOI : 10.1186/s13000-018-0689-9
URL : https://diagnosticpathology.biomedcentral.com/track/pdf/10.1186/s13000-018-0689-9
, , pp.22-25
Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer, Journal of Thoracic Oncology, vol.12, issue.10, pp.1536-1579, 2017. ,
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data, J Immunol Res. Hindawi, issue.11, pp.9839685-9839697, 2016. ,
PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of ,
, International Journal of Molecular Sciences, vol.17, issue.7, p.1046, 2016.
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types, International Journal of Molecular Sciences, vol.17, issue.5, 2016. ,
Association of PD-1, PD-1 ligands, and other features of the tumor immune micro-environment with response to anti-PD-1 therapy, Clin Cancer Res, vol.20, 2014. ,
Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol, vol.31, pp.214-248, 2018. ,
Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Advancing the boundaries of molecular cellular pathology, vol.70, pp.34-42, 2014. ,
Antibody validation, BioTechniques, vol.48, issue.3, pp.197-209, 2010. ,
Working towards a consensus for antibody validation, vol.3, p.266, 1000. ,
DOI : 10.12688/f1000research.5668.1
URL : https://f1000research.com/articles/3-266/v1/pdf